Liraglutide, a Once-Daily Human GLP-1 Analog, Reduces Systolic Blood Pressure with Minimal Impact from Weight Loss in Subjects with Type 2 Diabetes.

被引：0
|
作者：
Henry, R. R. [1 ]
Fonseca, V. [2 ]
Tabanera y Palacios, R. [3 ]
Brett, J. [4 ]
Plutzky, J. [5 ]
机构：
[1] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[2] Tulane Univ, Med Ctr, New Orleans, LA USA
[3] Novo Nordisk AS, Copenhagen, Denmark
[4] Novo Nordisk Inc, Princeton, NJ USA
[5] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
来源：
ENDOCRINE REVIEWS | 2010年 / 31卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes
    Marre, Michel
    Shaw, Jonathan
    Brandle, Michael
    Bebakar, Wan Mohamad Wan
    Kamaruddin, Nor Azmi
    Strand, Jorma
    Zdravkovic, Milan
    Le-Thi, Tu Duyen
    Colagiuri, Steven
    DIABETES, 2008, 57 : A4 - A4
  • [32] Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine:: All as add-on to metformin and a sulfonylurea in type 2 diabetes
    Russell-Jones, David
    Vaag, Allan
    Schmitz, Ole
    Sethi, Bipin K.
    Lalic, Nebojsa
    Antic, Slobodan S.
    Zdravkovic, Milan
    Ravn, Gabriela M.
    Simo, Rafael
    DIABETES, 2008, 57 : A159 - A160
  • [33] The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials
    Plutzky, J.
    Garber, A. J.
    Falahati, A.
    Toft, A. D.
    Poulter, N. R.
    EUROPEAN HEART JOURNAL, 2009, 30 : 917 - 917
  • [34] Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes
    Plutzky, J.
    Garber, A.
    Toft, A. D.
    Poulter, N. R.
    DIABETOLOGIA, 2009, 52 : S299 - S300
  • [35] Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
    Horowitz, Michael
    Flint, Anne
    Jones, Karen L.
    Hindsberger, Charlotte
    Rasmussen, Mads F.
    Kapitza, Christoph
    Doran, Selena
    Jax, Thomas
    Zdravkovic, Milan
    Chapman, Ian M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (02) : 258 - 266
  • [36] Liraglutide, a Once-Daily Human GLP-1 Analog, Is Equally Effective and Tolerated Independent of Administration Time (Morning vs Evening)
    Kaku, Kohei
    Rasmussen, Mads
    Katayama, Yasuyuki
    Seino, Yutaka
    DIABETES, 2009, 58 : A144 - A144
  • [37] Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
    Hermansen, K.
    Nauck, M. A.
    Frid, A.
    Shah, N. S.
    Tankova, T.
    Mitha, I. H.
    During, M.
    Zdravkovic, M.
    Matthews, D.
    DIABETOLOGIA, 2008, 51 : S358 - S358
  • [38] Beneficial effect of the GLP-1 analogue liraglutide on blood pressure and cardiovascular biomarkers in subjects with Type 2 diabetes
    Vilsboell, T.
    Zdravkovic, M.
    Le-Thi, T.
    Krarup, T.
    Schmitz, O.
    Courreges, J.
    Verhoeven, R.
    Buganova, I.
    Madsbad, S.
    DIABETIC MEDICINE, 2007, 24 : 3 - 3
  • [39] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
    Horowitz, M.
    Vilsboll, T.
    Zdravkovic, M.
    Hammer, M.
    Madsbad, S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
  • [40] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012)
    Astrup, A.
    Carraro, R.
    Finer, N.
    Harper, A.
    Kunesova, M.
    Lean, M. E. J.
    Niskanen, L.
    Rasmussen, M. F.
    Rissanen, A.
    Roessner, S.
    Savolainen, M. J.
    Van Gaal, L.
    INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 890 - 890
12345